


WHAT IS CLAIMED IS:

1. A compound comprising a plurality of covalently-bound 2'-modified nucleosides having the formula:



5 wherein:

each B is a nucleobase;

one of X₁ or X₂ is O, and the other of X₁ or X₂ is S;

each R₁ is, independently, H, hydroxyl, C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, C₂-C₂₀ alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-

phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R_1 has the formula:



y_1 is 0 or 1;

y_2 is independently 0 to 10;


y_3 is 1 to 10;

E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;


each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q_1 and Q_2 , together, are
 5 joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:

10



I



II

wherein

Z_0 is O, S, or NH;

q^1 is from 0 to 10;

q^2 is from 1 to 10;

q^3 is 0 or 1;

q^4 is, 0, 1 or 2;

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8
 20 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from
 about 4 to about 7 carbon atoms, or having from about 3 to
 about 6 carbon atoms and 1 or 2 hetero atoms wherein said
 25 hetero atoms are selected from oxygen, nitrogen and sulfur,
 and wherein said ring system is aliphatic, unsaturated
 aliphatic, aromatic, or saturated or unsaturated
 heterocyclic; and

Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

5 n is from 2 to 50; and

m is 0 or 1.

2. The compound of claim 1 wherein R₁ is -O-CH₂-CH₂-O-CH₃.


3. The compound of claim 1 wherein n is about 5 to 10 about 50.

4. The compound of claim 1 wherein n is about 8 to about 30.

5. The compound of claim 1 wherein n is about 4 to about 15.

15 6. The compound of claim 1 wherein n is 2 to about
10.

~~7.~~ An oligonucleotide having the Formula:



wherein:

each B is a nucleobase;

X₁ is S;

5 X₂ is O;

each R₁, is, independently, H, hydroxyl, C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, C₂-C₂₀ alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter

molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or N-R₂₂-(R₂₃)_v;

5 ~~R₂₂ is C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, or C₂-C₂₀~~
alkynyl;

R₂₃ is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

20 or R_1 has the formula:



```
y1 is 0 or 1;
```

y2 is independently 0 to 10;

```
y3 is 1 to 10;
```


25 E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;

each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group,


a linker to a solid support; or Q_1 and Q_2 , together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

5

or R_1 has one of formula I or II:



I



II

wherein

10

Z_0 is O, S, or NH;

q^1 is from 0 to 10;

q^2 is from 1 to 10;

q^3 is 0 or 1;

q^4 is, 0, 1 or 2;

15

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and

25

Z_5 is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms,

alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(Q_1)(Q_2)$, OQ_1 , halo, SQ_1 or CN;

n is from 2 to 50; and

m is 0 or 1;

5 R_2 is H, a hydroxyl protecting group, or an oligonucleotide; and

R_3 is OH, an oligonucleotide, or a linker connected to a solid support.

8. The compound of claim 7 wherein R_1 is $-O-CH_2-CH_2-O-$
10 CH_3 .


9. The compound of claim 8 wherein R_2 is H, and R_3 is OH.

10. The compound of claim 8 wherein R_2 is a phosphodiester-linked oligonucleotide or a phosphorothioate
15 linked oligonucleotide.

11. The compound of claim 8 R_3 is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.


~~12.~~ R_2 and R_3 are each a phosphodiester-linked
20 oligonucleotide or a phosphorothioate linked oligonucleotide.

~~13.~~ A compound having the Formula:



wherein:

25 W^1 has the Formula:



wherein:

each B is a nucleobase;

one of X_1 or X_2 is O, and the other of X_1 or X_2 is S;

5 each R_1 , is, independently, H, hydroxyl, C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, C_2 - C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-

phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R_1 has the formula:



25

y_1 is 0 or 1;

y_2 is independently 0 to 10;


y_3 is 1 to 10;

E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;


each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q_1 and Q_2 , together, are
 5 joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:

10



I



II

wherein

Z_0 is O, S, or NH;

q^1 is from 0 to 10;

q^2 is from 1 to 10;

q^3 is 0 or 1;

q^4 is, 0, 1 or 2;

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8
 20 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from
 about 4 to about 7 carbon atoms, or having from about 3 to
 about 6 carbon atoms and 1 or 2 hetero atoms wherein said
 25 hetero atoms are selected from oxygen, nitrogen and sulfur,
 and wherein said ring system is aliphatic, unsaturated
 aliphatic, aromatic, or saturated or unsaturated
 heterocyclic; and


Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

5 n is from 2 to 50; and

m is 0 or 1;

R₂ is H, a hydroxyl protecting group, or an oligonucleotide;

W^3 has the Formula:



wherein R_3 is OH, an oligonucleotide, or a linker connected to a solid support; and

W^2 is a plurality of covalently bound nucleosides linked by phosphodiester or phosphorothioate linkages.

5 14. The compound of claim 13 wherein R_1 is $-O-CH_2-CH_2-O-CH_3$.

15 15. The compound of claim 14 wherein R_2 is H, and R_3 is OH.

10 16. The compound of claim 14 wherein n is about 5 to about 50.

15 17. The compound of claim 14 wherein n is about 8 to about 30.

15 18. The compound of claim 14 wherein n is about 4 to about 15.

15 19. The compound of claim 14 wherein n is 2 to about 10.

20 20. The compound of claim 14 wherein W^2 is a plurality of covalently bound nucleosides linked by phosphodiester linkages.

20 21. The compound of claim 14 wherein W^2 is a plurality of covalently bound nucleosides linked by phosphorothioate linkages.

25 22. A composition comprising a compound of claim 1 and an acceptable carrier.

23. A composition comprising a compound of claim 7 and an acceptable carrier.

24. A composition comprising a compound of claim 12 and an acceptable carrier.

5 25. A method of modulating the production or activity
of a protein in an organism, comprising contacting said
organism with a compound of claim 1.

26. A method of modulating the production or activity of a protein in an organism, comprising contacting said
10 organism with a compound of claim 7.

27. A method of modulating the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 13.

15 28. A method of treating an organism having a disease
characterized by the undesired production of a protein,
contacting said organism with a compound of claim 1.

AS 29. A method of treating an organism having a disease characterized by the undesired production of a protein, 20 contacting said organism with a compound of claim 7.

30. A method of treating an organism having a disease characterized by the undesired production of a protein, contacting said organism with a compound of claim 13.

31. A method of assaying a nucleic acid, comprising
25 contacting a solution suspected to contain said nucleic acid
with a compound of claim 1.

1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2. 3.	1. 2. 3.
1. 2. 3.	1. 2.<	

sub
AS

32. A method of assaying a nucleic acid, comprising contacting a solution suspected to contain said nucleic acid with a compound of claim 7.

33. A method of assaying a nucleic acid, comprising
5 contacting a solution suspected to contain said nucleic acid
with a compound of claim 13.

Add A^6